NASDAQ$FDMT
4D Molecular Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
4D Molecular Therapeutics Inc reported a net loss of $54.7 million for Q2 2025.
The company continued advancing its clinical pipeline with increased R&D spending focused on 4D-150 Phase 3 trials. Revenue remained minimal at $15 thousand from collaboration agreements. Cash position stood at $77.2 million with total assets of $473.6 million as operations consumed $91.1 million in cash during the first half of the year.
- Net loss widened to $54.7 million from $35.0 million in Q2 2024 due to higher R&D expenses of $48.0 million.
- R&D expenses rose 51% year-over-year to support Phase 3 trials for 4D-150 in wet AMD.
- Cash and cash equivalents declined to $77.2 million from $149.3 million at year-end 2024.
- Accumulated deficit increased to $678.8 million reflecting ongoing development investments.
Headline financials
Revenue & EPS history
4DMT · Revenue · Quarterly
$15K
Revenue by segment
4DMT · $15K total across 1 segment · Q2 2025
- Collaboration and license revenue$15K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+1.0%
Avg return
Earnings day
+2.5%
Avg return
5 days after
+8.5%
Avg return
30 days after
45%
9 / 20 earnings
Positive
+20.0%
Q3 2022
Best reaction
-10.4%
Q2 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -4.6% | -0.7% | -17.3% | |
| Q4 2025 | +7.3% | +7.2% | +22.5% | |
| Q3 2025 | +6.7% | +6.1% | +7.4% | |
| Q1 2025 | +9.9% | +4.7% | +27.0% | |
| Q4 2024 | -8.6% | -8.6% | -28.7% | |
| Q3 2024 | +1.9% | +5.7% | -17.4% | |
| Q2 2024 | +0.6% | +1.6% | +2.4% | |
| Q1 2024 | -2.4% | -2.2% | -13.7% | |
| Q4 2023 | +5.3% | -3.0% | +14.2% | |
| Q3 2023 | +1.8% | +2.2% | +37.7% | |
| Q2 2023 | -1.6% | -1.1% | -7.4% | |
| Q1 2023 | -2.5% | +2.8% | +26.8% | |
| Q4 2022 | -0.7% | -5.4% | -12.5% | |
| Q3 2022 | +20.0% | +66.3% | +188.5% | |
| Q2 2022 | -10.4% | -12.5% | -14.9% | |
| Q1 2022 | -3.1% | -12.9% | -31.5% | |
| Q4 2021 | +8.1% | +1.6% | -22.5% | |
| Q3 2021 | -0.7% | -3.8% | -12.1% | |
| Q2 2021 | -4.0% | +5.2% | +19.4% | |
| Q1 2021 | -3.9% | -3.4% | +2.6% | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro